Welcome to our dedicated page for Qilian International Holding Group Ltd. Ordinary Shares news (Ticker: QLI), a resource for investors and traders seeking the latest updates and insights on Qilian International Holding Group Ltd. Ordinary Shares stock.
This news page for Qilian International Holding Group Ltd (historically Nasdaq: QLI) provides an archive of company announcements, regulatory updates and corporate actions that were released while the shares traded under the QLI ticker. The company has described itself as a China-based pharmaceutical and chemical products manufacturer, headquartered in Gansu, China, with a focus on licorice products, oxytetracycline products, traditional Chinese medicine derivatives products, heparin products, sausage casings, and fertilizers.
News items in this archive include communications about Nasdaq listing compliance, such as notifications of minimum bid price deficiencies, extensions to regain compliance, and the company’s subsequent confirmation that it had met the minimum bid price requirement. Readers will also find detailed announcements about the 1-for-5 reverse share split approved by the board of directors, including how the split affected Class A and Class B ordinary shares and the handling of fractional shares.
Other press releases cover strategic and industrial adjustments, where Qilian International outlined plans to reduce investment in oxytetracycline due to market and regulatory pressures, increase investment in heparin sodium, develop licorice-based products such as licorice extract, fluid extract and compound licorice lozenges, and allocate capital to financial products and software development. The archive also includes dividend declarations and interim financial result summaries that discuss revenue trends and segment performance across heparin products, oxytetracycline products, licorice products, traditional Chinese medicine derivatives, sausage casings and fertilizers.
In August 2024, the company announced that its Class A ordinary shares would begin trading under the ticker symbol BGM, replacing QLI, while remaining listed on the Nasdaq Capital Market. For users tracking the evolution of the business from QLI to BGM, this page offers historical context on how the company communicated with investors during that period.
Qilian International Holding Group , a China-based pharmaceutical and chemical products manufacturer, has announced a change in its trading ticker symbol on the Nasdaq Capital Market. Effective August 11, 2024, the company's Class A ordinary shares will trade under the new symbol 'BGM', replacing the current symbol 'QLI'. This change does not require any action from shareholders, and the company's CUSIP number remains unchanged. Qilian will continue to be listed on the Nasdaq Capital Market.
Qilian International Holding Group (NASDAQ: QLI), a China-based pharmaceutical and chemical products manufacturer, has regained compliance with NASDAQ's minimum bid price rule. On July 10, 2024, NASDAQ informed Qilian that for ten consecutive business days, from June 21 to July 9, 2024, the closing bid price of its Class A ordinary shares remained at or above $1.00 per share. This compliance with Listing Rule 5550(a)(2) means NASDAQ has closed the matter.
Qilian International Holding Group (NASDAQ: QLI) has announced a 1 for 5 reverse share split, effective June 21, 2024. Approved on May 29, 2023, this split will reduce the number of issued and outstanding Class A and Class B ordinary shares. The new Class A shares are expected to trade at five times their previous price, though this is not guaranteed. Shareholders will receive one new share for every five shares held. Post-split, Qilian's authorized share capital will consist of 70 million Class A shares, 20 million Class B shares, and 10 million preferred shares. Fractional shares will be rounded up to the nearest whole share.
Qilian International (NASDAQ: QLI) has announced plans to adjust its industrial investments in response to declining demand and increasing costs in its oxytetracycline sector. The company will significantly reduce its investment in oxytetracycline and increase its focus on heparin sodium, a biomedical raw material with promising market potential. Additionally, Qilian will expand its licorice product line and invest in financial technology and software development. These strategic shifts aim to optimize resource allocation, boost efficiency, and enhance overall competitiveness and profitability.
Summary not available.
Summary not available.
Qilian International Holding Group (NASDAQ: QLI) announced it has regained compliance with NASDAQ Listing Rule 5250(c)(1) after filing its annual report on Form 20-F on April 19, 2023. This report covered the financial year ended September 30, 2022, and resolved previous non-compliance issues cited in a notice received on February 16, 2023. Following the filing, NASDAQ confirmed the matter closed on April 20, 2023. Qilian, based in Gansu, China, specializes in manufacturing pharmaceutical and chemical products, including licorice and oxytetracycline products, serving over 20 provinces in China. The company emphasizes the importance of meeting regulatory requirements to maintain its listing status.
Qilian International Holding Group Ltd (NASDAQ: QLI) announced on February 23, 2023, that it received a notice of non-compliance from Nasdaq for not timely filing its annual report on Form 20-F for the year ending September 30, 2022. This notice does not immediately affect Qilian’s listing or trading on Nasdaq. The company has 60 days to submit a compliance plan, and if accepted, it could gain an additional 180 days until August 14, 2023, to comply with Nasdaq Listing Rule 5250(c)(1).
Qilian, based in Gansu, China, manufactures pharmaceutical and chemical products, selling in over 20 provinces.
On February 16, 2023, Qilian International Holding Group Ltd (NASDAQ: QLI) announced a special one-time cash dividend of
Qilian International Holding Group Limited (Nasdaq: QLI) reported financial results for the first six months of fiscal year 2022, ending March 31, 2022, showing revenues of approximately $32.1 million, up 7% year-over-year. However, net income plummeted by 89% to $249,681, primarily due to rising raw material costs. Gross profit decreased by 31% to $2.8 million, reflecting a decline in gross margin from 13.7% to 8.8%. The company expects growth in 2023 with the completion of ongoing construction projects and improved pandemic control.
FAQ
What is the current stock price of Qilian International Holding Group Ltd. Ordinary Shares (QLI)?
What is the market cap of Qilian International Holding Group Ltd. Ordinary Shares (QLI)?
